San Antonio — Cardiovate, an early stage San Antonio startup that aims to repair or replace clogged arteries with regenerated tissue has closed a small financing round from angel investors, The University of Texas Horizon Fund, and Targeted Technology, according to its CEO.

The startup founded in 2012, closed a $350,000 round of convertible notes from the investors in August, according to CEO Mark Standeford, who joined Cardiovate in 2014. The company plans to use that money, as well as an additional $150,000 it may seek, for patent legal work and to start a year-long animal study of its medical device, Standeford says.